|
US2014187606A1
|
|
Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN
|
|
US2013245099A1
|
|
Antagonat compositions and methods of use
|
|
US2013210893A1
|
|
Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
|
|
WO2011146674A2
|
|
Treatment of bcl2-like 11 (bcl2l11) related diseases by inhibition of natural antisense transcript to bcl2l11
|
|
US2013035372A1
|
|
Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3
|
|
WO2011097582A2
|
|
Treatment of arachidonate 12-lipoxygenase, 12r type (alox12b) related diseases by inhibition of natural antisense transcript to alox12b
|
|
US2012322853A1
|
|
Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
|
|
US2012295953A1
|
|
Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
|
|
WO2011038205A2
|
|
Treatment of growth hormone (gh) related diseases by inhibition of natural antisense transcript to gh
|
|
WO2011025862A2
|
|
Treatment of atp-binding cassette sub-family b member 1 (abcb1) related diseases by inhibition of natural antisense transcript to abcb1
|
|
US2012252869A1
|
|
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
|
US2011319476A1
|
|
Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
|
|
US2011237651A1
|
|
Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO
|
